Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck senior exec Frank Clyburn to depart

By Brian Buntz | January 20, 2022

MerckMerck & Co. (NYSE:MRK) has revealed that Frank Clyburn, executive vice president and president, Human Health, will depart the company on Feb. 1, 2022.

At Merck, Clyburn had P&L responsibility for almost 90% of Merck’s business.
Clyburn will assume the CEO role at International Flavors & Fragrances (IFF/NYSE:IFF) on Feb. 14.

“I’m excited to join IFF, an industry leader with a bright future, and to lead IFF to continue to deliver outstanding customer experience and sustained long-term growth,” Clyburn wrote on LinkedIn.

At IFF, he will receive a base salary of $1.3 million.

Frank Clyburn

Frank Clyburn

Clyburn joined Merck in 2008.

Clyburn was involved in launching Merck’s blockbuster drug Keytruda. In 2020, Keytruda racked up $14.4 billion in global sales, making it the second-best-selling drug of that year.

“Frank’s strategic and operational excellence helped establish Merck as a global leader in oncology,” said Robert M. Davis, Merck’s CEO and president, in a statement. “Our human health business has delivered strong and sustainable growth under Frank’s leadership, and we are well-positioned to continue this momentum with the strong human health team we have in place.”

Merck is currently looking for a replacement leader of its Human Health division and plans on making an announcement in the coming weeks.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE